MX2022004582A - Anticuerpo humanizado marcado con ri. - Google Patents

Anticuerpo humanizado marcado con ri.

Info

Publication number
MX2022004582A
MX2022004582A MX2022004582A MX2022004582A MX2022004582A MX 2022004582 A MX2022004582 A MX 2022004582A MX 2022004582 A MX2022004582 A MX 2022004582A MX 2022004582 A MX2022004582 A MX 2022004582A MX 2022004582 A MX2022004582 A MX 2022004582A
Authority
MX
Mexico
Prior art keywords
muc5ac
humanized antibody
antibody
radionuclide
labeled humanized
Prior art date
Application number
MX2022004582A
Other languages
English (en)
Inventor
Nobuya KOBASHI
Mitsuhiro Matono
Norihito NAKATA
Yoshinari SHOYAMA
Yasushi Ochiai
Takayuki Murakami
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of MX2022004582A publication Critical patent/MX2022004582A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)

Abstract

El anticuerpo humanizado anti-MUC5AC marcado con RI de la presente invención es un conjugado de un agente quelante quelado con un radionucleido y un anticuerpo (el radionucleido mencionado anteriormente es un nucleido metálico que emite un positrón o partícula a, y el anticuerpo mencionado anteriormente es un anticuerpo humanizado específicamente de unión a MUC5AC), y es superior en especificidad para MUC5AC y acumulación en el tumor; por lo tanto, es extremadamente útil para el tratamiento y/o diagnóstico de enfermedades en las que se sobreexpresa MUC5AC, particularmente el cáncer.
MX2022004582A 2019-10-18 2020-10-16 Anticuerpo humanizado marcado con ri. MX2022004582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019191562 2019-10-18
PCT/JP2020/039074 WO2021075544A1 (ja) 2019-10-18 2020-10-16 Ｒｉ標識されたヒト化抗体

Publications (1)

Publication Number Publication Date
MX2022004582A true MX2022004582A (es) 2022-07-21

Family

ID=75538071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004582A MX2022004582A (es) 2019-10-18 2020-10-16 Anticuerpo humanizado marcado con ri.

Country Status (13)

Country Link
US (2) US11369701B2 (es)
EP (1) EP4049684A4 (es)
JP (2) JP7036996B2 (es)
KR (1) KR20220084135A (es)
CN (1) CN114585393B (es)
AU (1) AU2020367415A1 (es)
BR (1) BR112022007313A2 (es)
CA (1) CA3158322A1 (es)
IL (1) IL292133A (es)
MX (1) MX2022004582A (es)
TW (1) TW202128230A (es)
WO (1) WO2021075544A1 (es)
ZA (1) ZA202205226B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233247A (zh) * 2020-10-16 2022-09-01 日商日本醫事物理股份有限公司 抗ｈｅｒ２抗體之放射性複合體及放射性醫藥
WO2022224980A1 (ja) * 2021-04-20 2022-10-27 日本メジフィジックス株式会社 抗ｃｄ２０抗体の放射性複合体、及び、放射性医薬
JPWO2022225006A1 (es) * 2021-04-21 2022-10-27
WO2023157822A1 (ja) * 2022-02-15 2023-08-24 日本メジフィジックス株式会社 抗ｖｅｇｆ抗体の放射性複合体、及び、放射性医薬
WO2024090488A1 (ja) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 放射性医薬組成物
WO2024090489A1 (ja) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203974A (ja) 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
JPH115749A (ja) 1997-06-13 1999-01-12 Tosoh Corp 癌治療医薬品組成物
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
SE0200943D0 (sv) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
CN102137681B (zh) * 2008-08-08 2014-12-03 埃姆诺医药有限公司 抗胰腺癌抗体
AU2011230313B2 (en) 2010-03-24 2015-01-22 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
US9107960B2 (en) * 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US20160303258A1 (en) 2013-12-03 2016-10-20 Millennium Pharmaceuticals, Inc. Compounds and compositions for imaging gcc-expressing cells
WO2016003869A1 (en) * 2014-06-30 2016-01-07 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
KR102651537B1 (ko) 2015-05-20 2024-03-25 가고시마 유니버시티 IgG 결합 펩타이드에 의한 항체의 특이적 변형
JP6959616B2 (ja) * 2016-06-13 2021-11-02 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチドによる部位特異的ＲＩ標識抗体
JP7191938B2 (ja) * 2017-05-05 2022-12-19 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション Ｉｇｆ－１ｒモノクローナル抗体及びその使用
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
US11701440B2 (en) 2018-04-16 2023-07-18 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
JP7242325B2 (ja) 2018-04-20 2023-03-20 キヤノン株式会社 画像形成装置
TW202123969A (zh) * 2019-10-18 2021-07-01 日商大日本住友製藥股份有限公司 人類化抗體或其抗原結合片段、此等之製造方法及用途

Also Published As

Publication number Publication date
CA3158322A1 (en) 2021-04-22
AU2020367415A1 (en) 2022-05-19
WO2021075544A1 (ja) 2021-04-22
CN114585393A (zh) 2022-06-03
JP7036996B2 (ja) 2022-03-15
US20210338852A1 (en) 2021-11-04
US11369701B2 (en) 2022-06-28
TW202128230A (zh) 2021-08-01
KR20220084135A (ko) 2022-06-21
BR112022007313A2 (pt) 2022-07-05
JP2022088398A (ja) 2022-06-14
ZA202205226B (en) 2023-11-29
EP4049684A4 (en) 2023-10-25
EP4049684A1 (en) 2022-08-31
CN114585393B (zh) 2024-08-13
IL292133A (en) 2022-06-01
US20230094773A1 (en) 2023-03-30
JPWO2021075544A1 (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2022004582A (es) Anticuerpo humanizado marcado con ri.
PH12020550898A1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EA202193076A1 (ru) Макроциклические хелаторы и способы их применения
JOP20210289A1 (ar) مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2022002401A (es) Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2017005976A (es) Moleculas de union especificas para grupo de diferenciacion 73 (cd73) y usos de las mismas.
PH12017502270A1 (en) Combination therapy for the treatment of cancer
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
ZA201907225B (en) Treatment of her2 positive cancers
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2019013753A (es) Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA202090116A1 (ru) Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2020012539A (es) Anticuerpos especificos para cd3 y sus usos.
MX2020011823A (es) Metodos para tratar cancer con combinacion de anticuerpo anti-muerte programada-1 (pd-1) y conjugado de anticuerpo anti-factor de tejido y farmaco.
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.